Similarly, Song et al. (2013) demonstrated the effectiveness of dorsomorphin in attenuating the over-activation of BMP signaling in pnpla6 morphants, suggesting its potential for clinical trials in treating spastic paraplegia (SPG) phenotypes caused by the disturbances in BMP signaling. This evidence concerns the gene PNPLA6 and hereditary spastic paraplegia.